rheumatologyadvisor.com
Prescription NSAID Use Not Linked to Overall Increase in IBD Hospitalization Risk
Many people with IBD avoid NSAIDs because of flare concerns. This large study suggests prescription NSAIDs did not meaningfully increase hospitalization risk overall, but patients with Crohn disease showed a higher risk. That could affect pain-treatment decisions.
Adults with IBD (especially Crohn disease), clinicians managing IBD pain or musculoskeletal comorbidities, and caregivers involved in medication decisions.
What To Know
Prescription NSAID use was not associated with a clinically meaningful increase in IBD-related hospitalization overall in a large retrospective claims study, but subgroup analyses found a higher hospitalization risk among patients with Crohn disease.
The study used Optum claims from 2000–2022, matched new NSAID recipients to unexposed patients, and applied propensity weighting and Cox models. Overall HR was 1.07 (CI 1.04–1.10) within the study’s noninferiority margin; for Crohn disease the HR was 1.16 (CI 1.12–1.21), exceeding that margin.
The authors note limitations typical of observational claims research, including potential residual confounding and lack of data on over-the-counter NSAID use and milder flares not leading to hospitalization.
The article suggests NSAIDs may be acceptable for select patients with clear indications (for example, significant musculoskeletal disease), but that Crohn disease patients may merit more caution.
If you are using or considering NSAIDs, discuss risks and alternatives with your gastroenterologist or primary care provider—especially if you have Crohn disease, a recent hospitalization, or active symptoms.
This is an observational claims study with potential residual confounding and no capture of over-the-counter NSAID use or milder flares. Results do not prove causation and should be interpreted alongside clinical judgment and individual risk factors.
